{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gralise%C2%AE",
    "query": {
      "intervention": "Gralise®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gralise%C2%AE&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T13:44:33.976Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07777965",
      "title": "Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Non-dependent, Recreational Sedative Users"
      ],
      "interventions": [
        {
          "name": "Alprazolam (Xanax)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin (Neurontin® (Registered Trademark))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2026-06-18",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07777965"
    },
    {
      "nct_id": "NCT01764464",
      "title": "GRASSP: Gralise® for Spine Surgery Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-laminectomy Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Gralise®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 53,
      "start_date": "2012-12",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01764464"
    },
    {
      "nct_id": "NCT00778401",
      "title": "Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Gabapentin tablets 800 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2002-10",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2008-10-23",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778401"
    },
    {
      "nct_id": "NCT00865059",
      "title": "A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Gabapentin 800 mg Tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "NEURONTIN® 800 mg Tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2001-02",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865059"
    },
    {
      "nct_id": "NCT01678911",
      "title": "Efficacy of Gralise® for Chronic Pelvic Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Irritable Bowel Syndrome",
        "Ulcerative Colitis",
        "Interstitial Cystitis",
        "Prostatitis",
        "Pelvic Pain"
      ],
      "interventions": [
        {
          "name": "Gralise",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2012-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-06-29",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01678911"
    },
    {
      "nct_id": "NCT00570388",
      "title": "Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "Prometa Treatment Program",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute of Addiction Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2007-03",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2008-01-16",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570388"
    },
    {
      "nct_id": "NCT00904202",
      "title": "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postherpetic Neuralgia",
        "Diabetic Neuropathy",
        "Complex Regional Pain Syndrome",
        "Carpal Tunnel Syndrome",
        "HIV Neuropathy",
        "Idiopathic Sensory Neuropathy",
        "Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Placebo Capsules + Placebo Patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules + Lidoderm®",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin + Lidoderm®",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin 300 mg capsules 1800 mg/day + placebo patch",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin 1800 mg/day + Lidoderm patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-01-02",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00904202"
    },
    {
      "nct_id": "NCT05319756",
      "title": "Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Abuse Potential"
      ],
      "interventions": [
        {
          "name": "gabapentin 600 mg",
          "type": "DRUG"
        },
        {
          "name": "gabapentin 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "gabapentin 600 mg and oxycodone HCl 20 mg",
          "type": "DRUG"
        },
        {
          "name": "gabapentin 1200 mg and oxycodone HCl 20 mg",
          "type": "DRUG"
        },
        {
          "name": "oxycodone HCl 20 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Specialty LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-04-30",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Marlton, New Jersey",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319756"
    },
    {
      "nct_id": "NCT00619983",
      "title": "Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Neuropathic Pain",
        "Chronic Low Back Pain"
      ],
      "interventions": [
        {
          "name": "donepezil",
          "type": "DRUG"
        },
        {
          "name": "duloxetine",
          "type": "DRUG"
        },
        {
          "name": "donepezil 2.5 mg and duloxetine 30mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2018-09-11",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 2,
      "location_summary": "Winston-Salem, North Carolina • Cleveland, Ohio",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00619983"
    },
    {
      "nct_id": "NCT04570436",
      "title": "Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Abuse Potential"
      ],
      "interventions": [
        {
          "name": "gabapentin 600 mg",
          "type": "DRUG"
        },
        {
          "name": "gabapentin 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "gabapentin 1800 mg",
          "type": "DRUG"
        },
        {
          "name": "diazepam 20 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Viatris Specialty LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-03-29",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-09-11T13:44:33.976Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04570436"
    }
  ]
}